PharmaEssentia wins Health Canada approval for BESREMi in polycythemia vera
Read how Health Canada’s BESREMi approval could reshape polycythemia vera treatment, reimbursement and PharmaEssentia’s Canadian strategy.
Pharma & Biotech
Pharma & Biotech
FDA approves BESREMi Pen as PharmaEssentia targets easier long-term polycythemia vera treatment
FDA approval brings BESREMi Pen to U.S. polycythemia vera care. Find out how convenience, safety and access may shape adoption.
Pharma & Biotech
Why Incyte INCA033989 could reshape essential thrombocythemia and myelofibrosis care
Find out how Incyte INCA033989 data could reshape CALR-mutated myelofibrosis and essential thrombocythemia treatment.
Pharma & Biotech
Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?
PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.
Pharma & Biotech
Can Jakafi XR defend Incyte’s ruxolitinib franchise as dosing convenience becomes strategic?
Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.
Pharma & Biotech
Can AN2 Therapeutics reposition epetraborole for polycythemia vera and reshape hematocrit control strategies?
AN2 Therapeutics plans a Phase 2 trial of epetraborole for polycythemia vera. Explore what this strategy could mean for future hematology treatments.
Pharma & Biotech
PharmaEssentia Corporation secures Japan approval for high-dose BESREMi regimen in polycythemia vera
Japan approves high-dose BESREMi regimen for polycythemia vera. Read the full analysis on safety, adoption, and what clinicians will watch next.
Pharma & Biotech
How Prelude Therapeutics is advancing a JAK2 JH2 strategy into the clinic after FDA IND clearance
FDA clears Prelude Therapeutics’ IND for PRT12396. Discover what this mutant-selective JAK2 approach could change for MPN drug development.